Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies

Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:641-662. doi: 10.1146/annurev-pharmtox-052120-084449. Epub 2021 Sep 27.

Abstract

Epilepsy is an etiologically heterogeneous condition; however, genetic factors are thought to play a role in most patients. For those with infantile-onset developmental and epileptic encephalopathy (DEE), a genetic diagnosis is now obtained in more than 50% of patients. There is considerable motivation to utilize these molecular diagnostic data to help guide treatment, as children with DEEs often have drug-resistant seizures as well as developmental impairment related to cerebral epileptiform activity. Precision medicine approaches have the potential to dramatically improve the quality of life for these children and their families. At present, treatment can be targeted for patients with diagnoses in many genetic causes of infantile-onset DEE, including genes encoding sodium or potassium channel subunits, tuberous sclerosis, and congenital metabolic diseases. Precision medicine may refer to more intelligent choices of conventional antiseizure medications, repurposed agents previously used for other indications, novel compounds, enzyme replacement, or gene therapy approaches.

Keywords: antisense oligonucleotides; developmental and epileptic encephalopathy; epilepsy; gene therapy; precision medicine.

MeSH terms

  • Brain Diseases*
  • Child
  • Humans
  • Precision Medicine*
  • Quality of Life